Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Resomelagon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resomelagon SCHEMBL31103565 | 1.00 | RAB9A (0.41) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL28929656 | 1.00 | RAB9A (0.41) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30084719 | 0.95 | MAPT (0.41) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30065112 | 0.94 | RAB9A (0.39) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30064265 | 0.94 | RAB9A (0.39) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30853066 | 0.93 | ALDH1A1 (0.45) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30853069 | 0.93 | MAPT (0.40) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL22658047 | 0.93 | ALDH1A1 (0.45) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL28929658 | 0.93 | ALDH1A1 (0.45) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL31103411 | 0.93 | ALDH1A1 (0.46) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117642382-A | Phenylpyrrole aminoguanidine salts and formulations | 西奈克制药有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-118613260-A | Treatment of rheumatoid arthritis | 西奈克制药有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-117642382-A | Phenylpyrrole aminoguanidine salts and formulations | 西奈克制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115362002-A | Symptomatic viral disease treatment | 西奈克制药有限公司 | 2022-11-18 | — | — | CN | disclosed |